Healionics bags $1.7m in first financing round:
This article was originally published in Clinica
Healionics, a Redmond, Washington-based biomaterials start-up, has secured $1.7m in a series A financing round led by individual private investors. The funds will be used to scale up manufacturing of the firm's STAR (sphere templated angiogenic regenerative) material technology, expand and accelerate preclinical studies of the product and advance the company's business development activities. STAR is designed to enhance biocompatibility of medical devices intended for implantation in the body and to promote healing. Healionics has inked several agreements to apply the STAR material in diabetes, wound care and infusion therapy.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.